A 53-year-old cisgender woman has taken bictegravir-tenofovir alafenamide-emtricitabine for approximately 8 months and has gained 11 pounds. She wants to switch to a different regimen. She has never developed HIV drug resistance and consistently has HIV RNA levels less than 40 copies/mL. She is immune to hepatitis B virus (HBV). She also has gastroesophageal reflux and takes omeprazole 40 mg once daily, but she never takes antacids.
Considering potential drug interactions, switching to which one of the following antiretroviral regimens would potentially be most problematic?
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
August 28th, 2024
August 28th, 2024
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5